Key Highlights
- Moderna has committed to a $950 million upfront payment to Arbutus Biopharma and Genevant Sciences, resolving patent litigation regarding COVID vaccine technology.
- An additional $1.3 billion payment may be required within 90 days should Moderna’s federal appeal fail.
- This agreement represents the largest patent settlement in pharmaceutical industry history and ranks second across all sectors.
- Following the announcement, Moderna shares surged 8.7% in after-hours trading, reaching $54.15.
- The company forecasts cash reserves between $4.5 billion and $5 billion by the end of 2026, with overall liquidity reaching $5.9 billion.
Moderna has brought its extended patent litigation to a close — and investors responded enthusiastically.
On Tuesday evening, the biotechnology firm revealed plans to deliver a $950 million single payment to Arbutus Biopharma (ABUS) and Genevant Sciences, a private entity, ending worldwide patent litigation concerning its Spikevax and mResvia vaccines.
The legal battle revolved around lipid nanoparticle (LNP) delivery technology, a critical component for transporting mRNA into cells. Arbutus and Genevant filed lawsuits against Moderna, alleging unauthorized use of their protected LNP technology.
Arbutus stock declined 11% to $4.20 during after-hours trading following the settlement announcement.
Moderna plans to record the $950 million expense during the first quarter of 2026, with the actual payment scheduled for the third quarter. Following this transaction, the company will face zero ongoing royalty obligations.
One condition remains outstanding. Moderna continues pursuing a federal circuit court appeal, asserting limited liability under its government contractor status. Should the appeal prove unsuccessful, the company has committed to an extra payment reaching $1.3 billion within a 90-day window.
The combined maximum obligation of $2.25 billion remains considerably lower than earlier projections. William Blair analysts highlighted that market participants had anticipated liability approaching $5 billion, which would have created significant liquidity challenges.
Under the settlement terms, Genevant is providing Moderna with worldwide non-exclusive licensing rights to its LNP delivery platform for specific mRNA vaccines. Genevant has further committed to refraining from future patent litigation against Moderna for designated patents.
Impact on Moderna’s Financial Position
Accounting for the settlement, Moderna projects cash and cash equivalents between $4.5 billion and $5 billion at the conclusion of 2026. The company maintains access to a $900 million credit facility, establishing total anticipated liquidity in the range of $5.4 billion to $5.9 billion.
CEO Stéphane Bancel emphasized that this agreement eliminates uncertainty and enables the organization to concentrate on future objectives.
Bancel anticipates Moderna achieving renewed revenue growth before 2026 concludes. The company seeks regulatory approval for its combined flu-COVID vaccine and a separate influenza vaccine during the current year.
Upcoming Clinical Developments and Pipeline Progress
Multiple clinical trial outcomes in oncology and rare disease programs are anticipated throughout 2026, which William Blair analysts identified as possible “new long-term growth drivers.”
This settlement eliminates a significant concern that had weighed on the stock. Moderna’s mRNA technology platform serves as the foundation for its extensive pipeline extending beyond coronavirus applications.
Both Arbutus and Genevant characterized the agreement as the largest publicly disclosed patent settlement in pharmaceutical industry history and the second-largest settlement across all business sectors.
Genevant CEO James Heyes called it “enormously gratifying” to be recognized for the company’s contribution to pandemic response.
Moderna’s stock price has increased more than 60% during the trailing twelve months, while the S&P 500 has delivered approximately 17% returns over the same timeframe.
The $950 million lump-sum payment is scheduled for delivery in the third quarter of 2026.
